Patents by Inventor Ikuko TAIRA

Ikuko TAIRA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant obligate anaerobic Gram-positive bacteria
    Patent number: 10882912
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 5, 2021
    Assignee: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • RECOMBINANT OBLIGATE ANAEROBIC GRAM-POSITIVE BACTERIA
    Publication number: 20190169305
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Application
    Filed: February 19, 2019
    Publication date: June 6, 2019
    Applicant: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • Recombinant obligate anaerobic gram-positive bacteria
    Patent number: 10266601
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 23, 2019
    Assignee: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • RECOMBINANT OBLIGATE ANAEROBIC GRAM-POSITIVE BACTERIA (As amended)
    Publication number: 20160326256
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Application
    Filed: December 24, 2014
    Publication date: November 10, 2016
    Inventors: Takeshi NISHIKAWA, Yuichiro TAIRA, Ikuko TAIRA, Isao ISHIDA